When the FDA approved Amgen Inc. and Allergan plc’s Kanjinti (trastuzumab-anns) on June 13 (see brief, p. 8), it became the fifth biosimilar of cancer drug Herceptin (trastuzumab), from Genentech Inc., a member of the Roche Group, that the agency has approved, as well as the 20th biosimilar overall. With the Herceptin biosimilars expected to become available later this year, almost half of commercial payers responding to a Zitter Insights survey say they expect to prefer biosimilar Herceptin over other similar drugs for the adjuvant treatment of breast cancer.
To access this post, you must purchase a subscription plan. Click Here to purchase.

Already a member? Click Here to login.